32-34 NEW PHARMA - In therapies PharmaTimes March explores today's life sciences landscape: patient autonomy where access to medicines is expected. Shifting politics, "super employees," ongoing innovation, GLP-1s, difficult-to-treat...

#obesity #diabetes #typeIIdiabetes #oncology #neurology #rarediseases #womenshealth #EliLilly #Akeso #SummitTherapeutics #precisionmedicine #immunotherapy #Alzheimersdisease #AstraZeneca #DaiichiSankyo #ADCs #precisiononcology #DrugstoWatch2026 #immunology #cardiology #CGTs
zurl.co/c8PJw

#SummitTherapeutics has moved ahead in the race to bring a therapy targeting both #VEGF and #PDL1 to market, after the #FDA started a review of its ivonescimab drug for #lungcancer.

buff.ly/PtZy4pn

Akeso Biopharma presenta la BLA de ivonescimab (anticuerpo biespecífico PD-1/VEGF) ante la FDA

📩 info@dengyuemed.com
🔗https://dengyuepharma.com

#Oncología #CáncerDePulmón #NSCLC #CPNM #EGFR #PD1 #VEGF #AnticuerpoBiespecífico #Ivonescimab #SummitTherapeutics #FDA

Summit Therapeutics stock rises after Akeso reports positive trial data Investing.com -- Summit Therapeutics plc (NASDAQ:SMMT) stock rose as much as 15% before paring gains to 2% after Akeso announced positive interim results from its HARMONi-A clinical trial for ivonescimab. In Akeso’s first half 2025 earnings report, the company disclosed that ivonescimab plus chemotherapy achieved a statistically significant and clinically meaningful overall survival (OS) benefit in the China-only HARMONi-A trial. The study evaluated the combination therapy against chemotherapy alone in second-line or later EGFR-mutated non-small cell lung cancer (NSCLC) patients. The positive OS data from HARMONi-A follows an earlier update presented at ASCO 2024, where the OS hazard ratio was 0.80 at 52% maturity. Akeso plans to present the updated data at an upcoming medical conference. While this development represents positive news for Summit Therapeutics, analysts note its impact on Summit’s overall prospects may be limited. Cantor analyst Eric Schmidt pointed out that the second-line EGFR+ NSCLC market represents a smaller opportunity compared to the first-line wild-type patient population, where ivonescimab is also being evaluated. The HARMONi-A results may not directly translate to U.S. approval prospects, as the separate HARMONi trial narrowly missed statistical significance for overall survival. However, the favorable maturation of survival data over time could be viewed positively. TD Cowen analyst Tyler Van Buren reiterated a Buy rating on Summit Therapeutics, noting that the positive HARMONi-A results "could derisk the additional exploratory analyses that Summit plans to run on the HARMONi trial, as the initial results just barely missed statistical significance." 3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. The fastest way to find out is with our Fair Value calculator. We use a mix of 17 proven industry valuation models for maximum accuracy. Get the bottom line for SMMT plus thousands of other stocks and find your next hidden gem with massive upside. Full access now available at 50% off while our Summer Sale lasts. Hurry, offer ends soon!

Click Subscribe #SummitTherapeutics #Akeso #stockmarket #investing #biotech

Summit climbs on rumour of $15bn AstraZeneca interest Is AstraZeneca about to join the ranks of pharma companies spending big bucks on PD(L)-1xVEGF bispecific antibodies for cancer?

Shares in #SummitTherapeutics have risen sharply on a report that #AstraZeneca is in discussions for a #partnership focused on PD-1xVEGF bispecific #ivonescimab that is estimated to be worth as much as $15 billion.

Summit Therapeutics stock rises after report of potential $15B AstraZeneca deal Investing.com -- Summit Therapeutics (NASDAQ:SMMT) stock rose 5% on Thursday while AstraZeneca (NASDAQ:AZN) shares fell 2% following a Bloomberg report that the companies are in discussions for a potential $15 billion partnership deal. According to the report, AstraZeneca is considering a licensing agreement for Summit’s ivonescimab lung cancer treatment. The deal structure could include a multi-billion dollar upfront payment followed by milestone payments that could bring the total value to approximately $15 billion over time. Summit has also reportedly been in talks with other major pharmaceutical companies about the experimental cancer drug, suggesting competitive interest in the treatment. The negotiations are still ongoing, and terms are being finalized, though the discussions could still fall apart or Summit might choose a different partner. Don't miss out on the next big opportunity! Stay ahead of the curve with ProPicks AI – 6 model portfolios fueled by AI stock picks with a stellar performance this year... In 2024 alone, ProPicks AI identified 2 stocks that surged over 150%, 4 additional stocks that leaped over 30%, and 3 more that climbed over 25%. That's an impressive track record. With portfolios tailored for Dow stocks, S&P stocks, Tech Stocks, and Mid Cap stocks, you can explore various wealth-building strategies. So if AZN is on your watchlist, it could be very wise to know whether or not it made the ProPicks AI lists.

Click Subscribe #SummitTherapeutics #AstraZeneca #StockMarket #Investing #Biotech

Today #SummitTherapeutics, last week at ODAC FDA panel rejected STARGLOW (COLUMVI) trial data as not applicable to US population because too many Chinese enrolled.

Food for thought for the Big Pharma deal makers rushing to #China for early clinical data.

Summit Therapeutics, Intel among Monday’s market cap stock movers Blog Mobile Portfolio Widgets About Us Advertise Help & Support Authors Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Click Subscribe #StockMarket #Investing #MarketCap #FinanceNews #SummitTherapeutics

Summit Therapeutics shares tumble following interim analysis Investing.com -- Summit Therapeutics Inc. (NASDAQ:SMMT) stock plummeted 37% after the company announced an interim analysis requested by Chinese health authorities showed a positive trend for its drug Ivonescimab compared to Pembrolizumab in PD-L1 positive advanced NSCLC, but failed to reassure investors. The analysis, part of the HARMONi-2 Phase III trial conducted in China, revealed a hazard ratio of 0.777 at 39% data maturity, suggesting a potential 22% reduction in the risk of death compared to Pembrolizumab. Despite these results, the market responded negatively, reflecting concerns over the preliminary nature of the data and the uncertainty it brings. Summit’s press release highlighted the approval of Ivonescimab by the NMPA in China for front-line PD-L1 positive advanced NSCLC and the company’s ongoing enrollment in the HARMONi-7 study. The global HARMONi-7 trial is evaluating Ivonescimab monotherapy against Pembrolizumab monotherapy with registration intent for the United States and other regions. Ivonescimab is a novel bispecific antibody that targets PD-1 and VEGF, potentially offering improved efficacy and safety over existing treatments. It is currently involved in multiple Phase III trials and has been administered to over 2,300 patients worldwide. Summit has initiated clinical development of Ivonescimab in NSCLC, with several trials underway, including HARMONi and HARMONi-3, and is activating sites in the United States for HARMONi-7. Despite the optimistic view from Summit’s leadership, the stock’s significant drop indicates that investors may be seeking more conclusive evidence of Ivonescimab’s efficacy and market potential. The company expects to announce top-line results from the HARMONi trial in the middle of this year, which may provide further clarity on the drug’s prospects and impact on the company’s financial performance. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Click Subscribe #StockMarket #Investing #FinanceNews #SummitTherapeutics #InvestmentStrategy

OncoInfluencers to Follow on Social Media: Howard Jack West - OncoDaily OncoInfluencers to Follow on Social Media: Howard Jack West / cancer, Howard Jack West, LinkedIn, Lung cancer, OncoDaily, oncoinfluencer, Oncoinfluencers to

OncoInfluencers to Follow on Social Media: Howard Jack West

oncodaily.com/career/211766

#Cancer #LungCancer #OncoDaily #Oncoinfluencer #OncoinfluencersToFollowOnSocialMedia #Oncology #SummitTherapeutics